Compare Recursion Pharmaceuticals Inc (RXRX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sana Biotechnology Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.6× Sana Biotechnology Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Sana Biotechnology Inc for 23 Days on average.
| RXRX | SANA | |
|---|---|---|
Market Cap | $2.14B | $836.71M |
Volume | 30,789,535 | 4,507,444 |
Sector | Health | Health |
52-Week High | $6.79 | $5.92 |
52-Week Low | $2.84 | $2.68 |
Typical Hold Time | 23 Days | 23 Days |
Enterprise Value | $1.66B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.95, down 7.49% in the last session, reflecting ongoing volatility. The company reported a net loss of $644.76M in 2025, with a negative net income margin of -961.97%, though recent quarters have shown mixed earnings beats. Technical indicators are bullish overall, with moving averages signaling strength. Strategic partnerships, such as the extended data license with Tempus AI (Business Wire, 2026-09-21), aim to bolster its AI-driven drug discovery platform, but high cash burn remains a concern.
The outlook is cautious; while analyst consensus is 40% buy and 60% hold (MarketBeat, 2026-09-20), the stock faces significant risks from persistent losses and slow revenue growth. Upside potential hinges on pipeline success, but investors must weigh the high valuation (P/S of 37.14) against operational challenges and competitive pressures in biotech.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
